Safety profile of miltefosine in the treatment of cutaneous leishmaniasis.

ABSTRACT: Cutaneous leishmaniasis (CL) is a neglected tropical disease that poses a significant public health challenge in Brazil and worldwide. Miltefosine, the only orally administered drug available for CL, was recently incorporated into Brazil's treatment protocols following recommendations by the World Health Organization (WHO) and revisions by national health authorities. While this represents an important advancement, miltefosine is associated with frequent gastrointestinal side effects and potential teratogenic risks, necessitating careful patient eligibility assessments and close clinical monitoring throughout treatment. Furthermore, the absence of national effectiveness data underscores the need for careful monitoring during large-scale implementation. This study, part of a broader impleme

SUBMITTER: Ribeiro LR 

PROVIDER: S-EPMC11643273 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature